Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

Jean D. Boyer, Michael Anand Chattergoon, Kenneth E. Ugen, Ami Shah, Mosi Bennett, Adam Cohen, Susan Nyland, Kim E. Lacy, Mark L. Bagarazzi, Terry J. Higgins, Yaela Baine, Richard B. Ciccarelli, Richard S. Ginsberg, Rob Roy MacGregor, David B. Weiner

Research output: Contribution to journalArticle

Abstract

A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.

Original languageEnglish (US)
Pages (from-to)100-107
Number of pages8
JournalClinical Immunology
Volume90
Issue number1
DOIs
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Cellular Immunity
HIV-1
DNA
rev Genes
CD4-Positive T-Lymphocytes
env Genes
DNA Vaccines
Histocompatibility Antigens Class II
Cytotoxic T-Lymphocytes
CD4 Lymphocyte Count
Antiviral Agents
Vaccines
HIV
Lymphocytes
Technology
Safety
Serum

Keywords

  • DNA vaccines
  • HIV-1
  • Immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Enhancement of cellular immune response in HIV-1 seropositive individuals : A DNA-based trial. / Boyer, Jean D.; Chattergoon, Michael Anand; Ugen, Kenneth E.; Shah, Ami; Bennett, Mosi; Cohen, Adam; Nyland, Susan; Lacy, Kim E.; Bagarazzi, Mark L.; Higgins, Terry J.; Baine, Yaela; Ciccarelli, Richard B.; Ginsberg, Richard S.; MacGregor, Rob Roy; Weiner, David B.

In: Clinical Immunology, Vol. 90, No. 1, 01.1999, p. 100-107.

Research output: Contribution to journalArticle

Boyer, JD, Chattergoon, MA, Ugen, KE, Shah, A, Bennett, M, Cohen, A, Nyland, S, Lacy, KE, Bagarazzi, ML, Higgins, TJ, Baine, Y, Ciccarelli, RB, Ginsberg, RS, MacGregor, RR & Weiner, DB 1999, 'Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial', Clinical Immunology, vol. 90, no. 1, pp. 100-107. https://doi.org/10.1006/clim.1998.4616
Boyer, Jean D. ; Chattergoon, Michael Anand ; Ugen, Kenneth E. ; Shah, Ami ; Bennett, Mosi ; Cohen, Adam ; Nyland, Susan ; Lacy, Kim E. ; Bagarazzi, Mark L. ; Higgins, Terry J. ; Baine, Yaela ; Ciccarelli, Richard B. ; Ginsberg, Richard S. ; MacGregor, Rob Roy ; Weiner, David B. / Enhancement of cellular immune response in HIV-1 seropositive individuals : A DNA-based trial. In: Clinical Immunology. 1999 ; Vol. 90, No. 1. pp. 100-107.
@article{5bf7b90495224b75a4196c1eb7dfaeea,
title = "Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial",
abstract = "A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.",
keywords = "DNA vaccines, HIV-1, Immunotherapy",
author = "Boyer, {Jean D.} and Chattergoon, {Michael Anand} and Ugen, {Kenneth E.} and Ami Shah and Mosi Bennett and Adam Cohen and Susan Nyland and Lacy, {Kim E.} and Bagarazzi, {Mark L.} and Higgins, {Terry J.} and Yaela Baine and Ciccarelli, {Richard B.} and Ginsberg, {Richard S.} and MacGregor, {Rob Roy} and Weiner, {David B.}",
year = "1999",
month = "1",
doi = "10.1006/clim.1998.4616",
language = "English (US)",
volume = "90",
pages = "100--107",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Enhancement of cellular immune response in HIV-1 seropositive individuals

T2 - A DNA-based trial

AU - Boyer, Jean D.

AU - Chattergoon, Michael Anand

AU - Ugen, Kenneth E.

AU - Shah, Ami

AU - Bennett, Mosi

AU - Cohen, Adam

AU - Nyland, Susan

AU - Lacy, Kim E.

AU - Bagarazzi, Mark L.

AU - Higgins, Terry J.

AU - Baine, Yaela

AU - Ciccarelli, Richard B.

AU - Ginsberg, Richard S.

AU - MacGregor, Rob Roy

AU - Weiner, David B.

PY - 1999/1

Y1 - 1999/1

N2 - A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.

AB - A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts ≥500/μl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 μg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV- 1 envelope was observed in multiple patients. Three of three patients in the 300-μg dose group also developed increased MIP-1α levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 μg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen- specific immune responses in humans.

KW - DNA vaccines

KW - HIV-1

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0032937060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032937060&partnerID=8YFLogxK

U2 - 10.1006/clim.1998.4616

DO - 10.1006/clim.1998.4616

M3 - Article

C2 - 9884357

AN - SCOPUS:0032937060

VL - 90

SP - 100

EP - 107

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -